Have a feature idea you'd love to see implemented?
Let us know!
AXDX Accelerate Diagnostics Inc
Price (delayed)
$1.77
Market cap
$41.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.99
Enterprise value
$75.73M
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC
Highlights
Accelerate Diagnostics's EPS has soared by 75% YoY and by 55% from the previous quarter
The company's net income has surged by 53% YoY and by 36% QoQ
The quick ratio rose by 45% YoY but it fell by 19% QoQ
AXDX's equity is down by 35% QoQ but it is up by 10% YoY
The gross margin fell by 37% YoY and by 6% QoQ
The gross profit has decreased by 34% YoY and by 5% QoQ
Key stats
What are the main financial stats of AXDX
Market
Valuations
Earnings
Shares outstanding
23.68M
Market cap
$41.91M
Enterprise value
$75.73M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.19
Revenue
$12.23M
EBIT
-$27.84M
EBITDA
-$24.47M
Free cash flow
-$33.43M
Per share
Balance sheet
Liquidity
EPS
-$1.99
Free cash flow per share
-$1.45
Book value per share
-$1.58
Revenue per share
$0.53
TBVPS
$0.99
Total assets
$22.87M
Total liabilities
$57.75M
Debt
$42.41M
Equity
-$34.89M
Working capital
$3.76M
Debt to equity
-1.22
Current ratio
1.28
Quick ratio
0.9
Net debt/EBITDA
-1.38
Margins
Efficiency
Dividend
EBITDA margin
-200%
Gross margin
17.5%
Net margin
-309.9%
Operating margin
-360.8%
Return on assets
-122%
Return on equity
N/A
Return on invested capital
-75.2%
Return on capital employed
-294.5%
Return on sales
-227.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AXDX stock price
How has the Accelerate Diagnostics stock price performed over time
Intraday
-1.12%
1 week
1.14%
1 month
15.69%
1 year
-71.45%
YTD
-54.85%
QTD
3.51%
Financial performance
How have Accelerate Diagnostics's revenue and profit performed over time
Revenue
$12.23M
Gross profit
$2.14M
Operating income
-$44.14M
Net income
-$37.91M
Gross margin
17.5%
Net margin
-309.9%
AXDX's net margin has soared by 55% YoY and by 36% QoQ
The company's net income has surged by 53% YoY and by 36% QoQ
The gross margin fell by 37% YoY and by 6% QoQ
The gross profit has decreased by 34% YoY and by 5% QoQ
Growth
What is Accelerate Diagnostics's growth rate over time
Valuation
What is Accelerate Diagnostics stock price valuation
P/E
N/A
P/B
N/A
P/S
3.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.19
Accelerate Diagnostics's EPS has soared by 75% YoY and by 55% from the previous quarter
AXDX's equity is down by 35% QoQ but it is up by 10% YoY
AXDX's price to sales (P/S) is 88% less than its 5-year quarterly average of 27.2 and 10% less than its last 4 quarters average of 3.7
The revenue has grown by 4.9% year-on-year
Efficiency
How efficient is Accelerate Diagnostics business performance
Accelerate Diagnostics's return on invested capital has surged by 69% YoY and by 59% QoQ
Accelerate Diagnostics's ROS has soared by 64% YoY and by 44% from the previous quarter
Accelerate Diagnostics's ROA has increased by 22% from the previous quarter and by 8% YoY
Dividends
What is AXDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AXDX.
Financial health
How did Accelerate Diagnostics financials performed over time
The company's total assets is 60% lower than its total liabilities
The company's current ratio has surged by 62% YoY but it fell by 15% QoQ
The company's total assets has shrunk by 54% YoY and by 26% QoQ
AXDX's equity is down by 35% QoQ but it is up by 10% YoY
Accelerate Diagnostics's debt to equity has decreased by 28% YoY but it has increased by 22% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.